Follow us on:

Linkedin Facebook

Globus Medical, Inc. – Consensus ‘hold’ rating and 19.2% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Globus Medical, Inc. with ticker code (GMED) have now 10 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between 77 and 61 calculating the mean target price we have $67.60. Given that the stocks previous close was at $56.73 this now indicates there is a potential upside of 19.2%. Also worth taking note is the 50 day moving average now sits at $56.09 and the 200 day MA is $63.74. The company has a market cap of 5.80B. The current share price for the company is: 57.07 USD

The potential market cap would be $6,912,722,988 based on the market consensus.

USD

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 29.42, revenue per share of 10.68 and a 7.39% return on assets.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Broker Ratings

    Globus Medical, Inc. Share Price Target ‘$90.54’, now 6.6% Upside Potential

    Broker Ratings

    Globus Medical, Inc. – Consensus ‘buy’ rating and 11.6% Upside Potential

    Broker Ratings

    Globus Medical, Inc. Share Price Target ‘$90.54’, now 9.7% Upside Potential

    Broker Ratings

    Globus Medical, Inc. – Consensus ‘buy’ rating and 10.5% Upside Potential

    Broker Ratings

    Globus Medical, Inc. Share Price Target ‘$79.54’, now 8.0% Upside Potential

    Broker Ratings

    Globus Medical, Inc. – Consensus ‘buy’ rating and 8.2% Upside Potential

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.